A Phase 3 interventional study of TEZ and TEZ/IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 33 sites in 2 countries. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2020-03-04.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tezacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. tezacaftor · Cystic Fibrosis.
Among the 43 studies testing tezacaftor in Cystic Fibrosis, this one is the 25th largest by enrollment, is one of 6 that started in 2016, is one of 25 in phase 3, and was the 11th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →4 of the 43 studies testing tezacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
tezacaftor: first FDA approval 2024 (ALYFTREK), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 6 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 25 · Phase 4 3
First in 2012; this study’s year is marked. 6 started in 2016.
This study's enrollment of 83 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 100 across the 43 interventional studies. Of the 36 that completed or were terminated, 31 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 5 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 52nd largest by enrollment of the 116 interventional ones that give a count, is one of 15 that started in 2016, is one of 62 in phase 3, and was the 57th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
4 of the studies testing tezacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 43 studies testing tezacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, 2-part (Part A and Part B), open label, multicenter study evaluating the pharmacokinetic (PK), safety, and tolerability of multiple doses of tezacaftor (TEZ) in combination with ivacaftor (IVA) in subjects 6 through 11 years of age with CF who are homozygous or heterozygous for the F508del- CF transmembrane conductance regulator protein (CFTR) mutation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The following genotypes are eligible in Part B:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants weighing \<25 kg received TEZ 50 mg once daily/IVA 75 mg q12h orally for 14 days. Participants weighing ≥25 kg received TEZ 50 mg once daily/IVA 150 mg q12h orally for 14 days.
Drug: TEZ · Drug: IVA
Participants weighing \<40 kg received TEZ 50 mg/IVA 75 mg as fixed dose combination orally once daily in the morning and IVA 75 mg orally once daily in the evening for 24 weeks. Participants weighing ≥40 kg received TEZ 100 mg/IVA 150 mg as fixed dose combination orally once daily in the morning and IVA 150 mg orally once daily in the evening for 24 weeks.
Drug: TEZ/IVA · Drug: IVA
Also known as: tezacaftor, VX-661
Drug pages: Tezacaftor · Ivacaftor
Also known as: tezacaftor/ivacaftor, VX-661/VX-770
Also known as: ivacaftor, VX-770
Part A: Maximum Observed Concentration (Cmax) of TEZ and IVA
Time frame: Day 1 and Day 14
Part A: Area Under the Concentration Versus Time Curve During Dosing Interval (AUCtau) of TEZ and IVA
Time frame: Day 1 and Day 14
Part B: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Day 1 up to Week 28
Part A: Cmax of TEZ Metabolites (M1-TEZ, M2-TEZ) and IVA Metabolites (M1-IVA, M6-IVA)
Time frame: Day 1 and Day 14
Part A: AUCtau of TEZ Metabolites (M1-TEZ, M2-TEZ) and IVA Metabolites (M1-IVA, M6-IVA)
Time frame: Day 1 and Day 14
Part A: Number of Participants With AEs and SAEs
Time frame: Day 1 up to Day 28
Part B: Cmax of TEZ, TEZ Metabolites (M1-TEZ, M2-TEZ), IVA, and IVA Metabolites (M1-IVA, M6-IVA)
Time frame: Week 16
Part B: AUCtau of TEZ, TEZ Metabolites (M1-TEZ, M2-TEZ), IVA, and IVA Metabolites (M1-IVA, M6-IVA )
Time frame: Week 16
Part B: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: From Baseline through Week 24
Part B: Relative Change in ppFEV1
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: From Baseline through Week 24
Part B: Absolute Change in Weight
Time frame: From Baseline at Week 24
Part B: Absolute Change in Weight-for-age Z-Score
z-score is a statistical measure to describe whether a mean was above or below the standard. Weight, adjusted for age and sex, was analyzed as weight-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher weight.
Time frame: From Baseline at Week 24
Part B: Absolute Change in Height
Time frame: From Baseline at Week 24
Part B: Absolute Change in Height-for-age z-Score
z-score is a statistical measure to describe whether a mean was above or below the standard. Height, adjusted for age and sex, was analyzed as height-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher height.
Time frame: From Baseline at Week 24
Part B: Absolute Change in Body Mass Index (BMI)
BMI was defined as weight in kg divided by height in square meter (m\^2).
Time frame: From Baseline at Week 24
Part B: Absolute Change in BMI-for-age z-Score
BMI was defined as weight in kg divided by height in m\^2. z-score is a statistical measure to describe whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher BMI.
Time frame: From Baseline at Week 24
Part B: Absolute Change in Sweat Chloride
Sweat samples were collected using an approved collection device.
Time frame: From Baseline through Week 4
Part B: Absolute Change in Sweat Chloride
Sweat samples were collected using an approved collection device.
Time frame: From Baseline through Week 24
Part B: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
Time frame: From Baseline through Week 24
| Milestone | Part A | Part B |
|---|---|---|
| Started | 13 | 70 |
| Completed | 13 | 67 |
| Not completed | 0 | 3 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Withdrawal of consent (not due to ae) | 0 | 2 |
| nanogram per milliliter (ng/mL) | Part A |
|---|---|
| Day 1: TEZ (<25 Kg) | 6630 ± 10.3 |
| Day 1: TEZ (≥25 Kg) | 4310 ± 42.6 |
| Day 14: TEZ (<25 Kg) | 6300 ± 10.3 |
| Day 14: TEZ (≥25 Kg) | 5340 ± 49.0 |
| Day 1: IVA (<25 Kg) | 656 |
| Day 1: IVA (≥25 Kg) | 1010 ± 64.3 |
| Day 14: IVA (<25 Kg) | 578 ± 60.4 |
| Day 14: IVA (≥25 Kg) | 1490 ± 105 |
| hour*nanogram per milliliter (hr*ng/mL) | Part A |
|---|---|
| Day 1: TEZ (<25 Kg) | 54300 ± 16.2 |
| Day 1: TEZ (≥25 Kg) | 41600 ± 36.2 |
| Day 14: TEZ (<25 Kg) | 66500 ± 30.5 |
| Day 14: TEZ (≥25 Kg) | 71600 ± 61.1 |
| Day 14: IVA (<25 Kg) | 5050 ± 49.1 |
| Day 14: IVA (≥25 Kg) | 12400 ± 118 |
| participants | Part B |
|---|---|
| Participants with AEs | 65 |
| Participants with SAEs | 6 |
| ng/mL | Part A |
|---|---|
| Day 1: M1-TEZ (<25 kg) | 1720 ± 3.29 |
| Day 1: M1-TEZ (≥25 kg) | 1530 ± 22.0 |
| Day 14: M1-TEZ (<25 kg) | 8360 ± 22 |
| Day 14: M1-TEZ (≥25 kg) | 5930 ± 19.9 |
| Day 1: M2-TEZ (<25 kg) | 1130 ± 4.36 |
| Day 1: M2-TEZ (≥25 kg) | 922 ± 25.8 |
| Day 14: M2-TEZ (<25 kg) | 6180 ± 27.2 |
| Day 14: M2-TEZ (≥25 kg) | 5350 ± 27.2 |
| Day 1: M1-IVA (<25 kg) | 2320 |
| Day 1: M1-IVA (≥25 kg) | 2430 ± 57.1 |
| Day 14: M1-IVA (<25 kg) | 1460 ± 34.6 |
| Day 14: M1-IVA (≥25 kg) | 3420 ± 72.7 |
| Day 1: M6-IVA (<25 kg) | 849 |
| Day 1: M6-IVA (≥25 kg) | 1070 ± 55.7 |
| Day 14: M6-IVA (<25 kg) | 1090 ± 31.4 |
| Day 14: M6-IVA (≥25 kg) | 2720 ± 59.2 |
| hr*ng/mL | Part A |
|---|---|
| Day 1: M1-TEZ (<25 kg) | 36500 ± 5.80 |
| Day 1: M1-TEZ (≥25 kg) | 27400 ± 26.3 |
| Day 14: M1-TEZ (<25 kg) | 160000 ± 15.5 |
| Day 14: M1-TEZ (≥25 kg) | 121000 ± 17.1 |
| Day 1: M2-TEZ (<25 kg) | 14200 ± 12.3 |
| Day 1: M2-TEZ (≥25 kg) | 11100 ± 25.9 |
| Day 14: M2-TEZ (<25 kg) | 137000 ± 32.7 |
| Day 14: M2-TEZ (≥25 kg) | 119000 ± 27.7 |
| Day 14: M1-IVA (<25 kg) | 13700 ± 52.1 |
| Day 14: M1-IVA (≥25 kg) | 30300 ± 81.1 |
| Day 14: M6-IVA (<25 kg) | 10200 ± 58.5 |
| Day 14: M6-IVA (≥25 kg) | 26000 ± 70.6 |
| participants | Part A |
|---|---|
| Participants with AEs | 12 |
| Participants with SAEs | 0 |
| ng/mL | Part B |
|---|---|
| TEZ (<40 kg) | 4800 ± 33.7 |
| TEZ (≥40 kg) | 5870 ± 46.5 |
| M1-TEZ (<40 kg) | 5310 ± 36.0 |
| M1-TEZ (≥40 kg) | 5440 ± 61.5 |
| M2-TEZ (<40 kg) | 4170 ± 47.4 |
| M2-TEZ (≥40 kg) | 5210 ± 55.0 |
| IVA (<40 kg) | 725 ± 56.9 |
| IVA (≥40 kg) | 886 ± 58.7 |
| M1-IVA (<40 kg) | 1560 ± 54.8 |
| M1-IVA (≥40 kg) | 1870 ± 50.2 |
| M6-IVA (<40 kg) | 870 ± 69.2 |
| M6-IVA (≥40 kg) | 1120 ± 29.5 |
| hr*ng/mL | Part B |
|---|---|
| TEZ (<40 kg) | 50300 ± 36.3 |
| TEZ (≥40 kg) | 60900 ± 50.6 |
| M1-TEZ (<40 kg) | 104000 ± 44.2 |
| M1-TEZ (≥40 kg) | 100000 ± 87.2 |
| M2-TEZ (<40 kg) | 88400 ± 57.0 |
| M2-TEZ (≥40 kg) | 93600 ± 46.5 |
| IVA (<40 kg) | 5330 ± 62.2 |
| IVA (≥40 kg) | 7410 ± 53.8 |
| M1-IVA (<40 kg) | 12700 ± 55.9 |
| M1-IVA (≥40 kg) | 17200 ± 40.4 |
| M6-IVA (<40 kg) | 8140 ± 70.2 |
| M6-IVA (≥40 kg) | 11100 ± 39.4 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percentage points | Part B |
|---|---|
| Part B: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) | 0.9 (-0.6 to 2.3) |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percent change | Part B |
|---|---|
| Part B: Relative Change in ppFEV1 | 1.4 (-0.4 to 3.1) |
| kg | Part B |
|---|---|
| Part B: Absolute Change in Weight | 1.7 (1.3 to 2.0) |
z-score is a statistical measure to describe whether a mean was above or below the standard. Weight, adjusted for age and sex, was analyzed as weight-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher weight.
| z-score | Part B |
|---|---|
| Part B: Absolute Change in Weight-for-age Z-Score | 0.00 (-0.05 to 0.05) |
| centimeter (cm) | Part B |
|---|---|
| Part B: Absolute Change in Height | 2.7 (2.4 to 2.9) |
z-score is a statistical measure to describe whether a mean was above or below the standard. Height, adjusted for age and sex, was analyzed as height-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher height.
| z-score | Part B |
|---|---|
| Part B: Absolute Change in Height-for-age z-Score | 0.00 (-0.05 to 0.05) |
BMI was defined as weight in kg divided by height in square meter (m\^2).
| kg/m^2 | Part B |
|---|---|
| Part B: Absolute Change in Body Mass Index (BMI) | 0.23 (0.06 to 0.40) |
BMI was defined as weight in kg divided by height in m\^2. z-score is a statistical measure to describe whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher BMI.
| z-score | Part B |
|---|---|
| Part B: Absolute Change in BMI-for-age z-Score | -0.03 (-0.10 to 0.04) |
Sweat samples were collected using an approved collection device.
| millimole per liter (mmol/L) | Part B |
|---|---|
| Part B: Absolute Change in Sweat Chloride | -13.0 (-16.2 to -9.9) |
Sweat samples were collected using an approved collection device.
| mmol/L | Part B |
|---|---|
| Part B: Absolute Change in Sweat Chloride | -14.5 (-17.4 to -11.6) |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
| units on a scale | Part B |
|---|---|
| Part B: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score | 3.4 (1.4 to 5.5) |
Collected over Part A: Day 1 up to Day 28; Part B: Day 1 up to Week 28. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A | 0/13 (0%) | 0/13 (0%) | 12/13 (92.3%) |
| Part B | 0/70 (0%) | 6/70 (8.6%) | 62/70 (88.6%) |
| Event | Part A | Part B |
|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 0/13 | 2/70 |
| ConstipationGastrointestinal disorders | 0/13 | 1/70 |
| Breath odourGastrointestinal disorders | 0/13 | 1/70 |
| SinusitisInfections and infestations | 0/13 | 1/70 |
| Failure to thriveMetabolism and nutrition disorders | 0/13 | 1/70 |
| SnoringRespiratory, thoracic and mediastinal disorders | 0/13 | 1/70 |
| Event | Part A | Part B |
|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 3/13 | 25/70 |
| HeadacheNervous system disorders | 3/13 | 6/70 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 0/13 | 15/70 |
| PyrexiaGeneral disorders | 1/13 | 13/70 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 2/13 | 10/70 |
| Abdominal painGastrointestinal disorders | 0/13 | 10/70 |
| VomitingGastrointestinal disorders | 0/13 | 7/70 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 0/13 | 7/70 |
| NasopharyngitisInfections and infestations | 1/13 | 6/70 |
| Upper respiratory tract infectionInfections and infestations | 0/13 | 6/70 |
| Age, Categorical(Participants) | Part A | Part B | Total |
|---|---|---|---|
| <=18 years | 13 | 70 | 83 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Part A | Part B | Total |
|---|---|---|---|
| Female | 7 | 34 | 41 |
| Male | 6 | 36 | 42 |
| Ethnicity (NIH/OMB)(Participants) | Part A | Part B | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 3 | 3 |
| Not Hispanic or Latino | 13 | 67 | 80 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part A | Part B | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 12 | 68 | 80 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2016 to primary completion in Sep 2018, 22 months.
Results were first posted in Dec 2019, 1 year 3 months after primary completion.
Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 22 months is below that.
Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tezacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →